ROMANA 3:阿那莫林治疗晚期非小细胞肺癌恶病质患者的3期安全性扩展研究
ROMANA 3是两项3期双盲研究的扩展研究,评估阿那莫林在晚期非小细胞肺癌恶病质患者中的安全性。完成ROMANA 1或2的12周治疗后,513例患者继续接受阿那莫林100 mg或安慰剂每日一次治疗12周。阿那莫林耐受性良好,体重和厌食-恶病质症状改善得以维持,但握力无显著改善。
要点
- 阿那莫林与安慰剂组治疗期不良事件发生率相似(52.2% vs 55.7%)。
- 阿那莫林在所有时间点较安慰剂显著增加体重(P < 0.0001)。
- 两组握力均无显著改善。
核心结论
- 在12-24周的ROMANA 3研究中,阿那莫林持续耐受性良好。
- 在整个0-24周治疗期间,阿那莫林改善了体重和症状负担。
研究设计与样本
- ROMANA 3是两项3期双盲研究(ROMANA 1和ROMANA 2)的安全性扩展研究。
- 完成ROMANA 1或ROMANA 2的12周治疗且美国东部肿瘤协作组评分≤2的晚期非小细胞肺癌恶病质患者可入组。
- 患者继续接受阿那莫林100 mg或安慰剂每日一次治疗额外12周(12-24周)。
- 共513例患者入组ROMANA 3(阿那莫林组N=345,平均年龄62.0岁;安慰剂组N=168,平均年龄62.2岁)。
- 主要终点为12-24周阿那莫林的安全性/耐受性。
主要发现
- 在ROMANA 3期间,阿那莫林组与安慰剂组治疗期不良事件发生率分别为52.2%和55.7%,≥3级治疗期不良事件发生率分别为22.4%和21.6%,严重治疗期不良事件发生率分别为12.8%和12.6%。
- 阿那莫林组和安慰剂组分别有36例(10.5%)和23例(13.8%)死亡,均与药物无关。
- 阿那莫林较安慰剂在所有时间点显著增加体重(P < 0.0001)。
- 阿那莫林在第3、6、9、12和16周改善厌食-恶病质症状(P < 0.05)。
- 两组握力均无显著改善。
关键数值与推荐
- 阿那莫林100 mg每日一次口服,安慰剂每日一次口服。
- 治疗期不良事件发生率:阿那莫林组52.2% vs 安慰剂组55.7%。
- ≥3级治疗期不良事件发生率:阿那莫林组22.4% vs 安慰剂组21.6%。
- 严重治疗期不良事件发生率:阿那莫林组12.8% vs 安慰剂组12.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities. PATIENTS AND METHODS: ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and efficacy of anamorelin in advanced NSCLC patients with cachexia. Patients with preserved Eastern Cooperative Oncology Group ≤2 after completing 12 weeks (w) on the ROMANA 1 or ROMANA 2 trials (0-12 weeks) could enroll in ROMANA 3 and continue to receive anamorelin 100 mg or placebo once daily for an additional 12w (12-24 weeks). The primary endpoint of ROMANA 3 was anamorelin safety/tolerability (12-24 weeks). Secondary endpoints included changes in body weight, handgrip strength (HGS), and symptom burden (0-24 weeks). RESULTS: Of the 703 patients who completed ROMANA 1 and ROMANA 2, 513 patients entered ROMANA 3 (anamorelin, N = 345, mean age 62.0 years; placebo, N = 168; mean age 62.2 years). During ROMANA 3, anamorelin and placebo groups had similar incidences of treatment-emergent adverse events (TEAEs; 52.2% versus 55.7%), grade ≥3 TEAEs (22.4% versus 21.6%), and serious TEAEs (12.8% versus 12.6%). There were 36 (10.5%) and 23 (13.8%) deaths in the anamorelin and placebo groups, respectively; none were drug-related. Improvements in body weight and anorexia-cachexia symptoms observed in the original trials were consistently maintained over 12-24 weeks. Anamorelin, versus placebo, significantly increased body weight from baseline of original trials at all time points (P < 0.0001) and improved anorexia-cachexia symptoms at weeks 3, 6, 9, 12, and 16 (P < 0.05). No significant improvement in HGS was seen in either group. CONCLUSION: During the 12-24 weeks ROMANA 3 trial, anamorelin continued to be well tolerated. Over the entire 0-24w treatment period, body weight and symptom burden were improved with anamorelin. CLINICAL TRIAL REGISTRATION NUMBERS: ROMANA 1 (NCT01387269), ROMANA 2 (NCT01387282), and ROMANA 3 (NCT01395914).
引用
- Currow D, Temel JS, Abernethy A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017. PMID: 28472437. doi:10.1093/annonc/mdx192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。